Analysis of the immune status in the whole blood of cancer patients
Recruiting
- Conditions
- Tumors of the liver, bile ducts, intestines, pancreas
- Registration Number
- DRKS00032078
- Lead Sponsor
- niklinik RWTH Aachen Allg.-, Viszeral- & Transplantationschirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Patients requiring surgical or chemotherapeutic treatment for cancer of the liver, bile ducts, intestines or pancreas.
Exclusion Criteria
Minors, pregnant women, persons incapable of giving consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study aims to address the following questions<br>- What is the variability of inducible cytokine formation for each tumor entity?<br>- Are there characteristic values for the different tumor entities?<br>- Does inducible cytokine production correlate with primary tumor staging?<br>- Are there differences between the healthy comparison group and the different tumor entities?<br>- Does inducible cytokine formation change with tumor removal or chemotherapeutic treatment?
- Secondary Outcome Measures
Name Time Method Secondary objectives are to determine the prognostic value of cytokine production for progression-free survival and to gain insight into the association of inducible cytokine production with vitamin D, C-reactive protein (CRP), and monocyte and lymphocyte counts.